HLS Therapeutics Inc.
HLS.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 12.26% | -18.78% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 12.26% | -18.78% | |||
| Cost of Revenue | 0.97% | -9.23% | |||
| Gross Profit | 17.19% | -22.34% | |||
| SG&A Expenses | -0.44% | -9.12% | |||
| Depreciation & Amortization | 2.29% | -1.36% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.91% | -6.49% | |||
| Operating Income | 64.49% | -630.33% | |||
| Income Before Tax | 43.96% | -51.77% | |||
| Income Tax Expenses | 1,152.17% | -127.06% | |||
| Earnings from Continuing Operations | 38.21% | -46.74% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 38.21% | -46.74% | |||
| EBIT | 64.49% | -630.33% | |||
| EBITDA | 48.47% | -37.73% | |||
| EPS Basic | 37.92% | 28.50% | |||
| Normalized Basic EPS | 43.67% | 25.99% | |||
| EPS Diluted | 35.71% | 31.67% | |||
| Normalized Diluted EPS | 43.67% | 25.99% | |||
| Average Basic Shares Outstanding | -0.48% | 5.17% | |||
| Average Diluted Shares Outstanding | -0.48% | 5.17% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||